Genomic Classifier Is One Piece of the ILD Diagnosis Puzzle Genomic Classifier Is One Piece of the ILD Diagnosis Puzzle
Although genomic testing is useful when an interstitial lung disease diagnosis is uncertain, the testing results themselves aren ' t sufficient to make the diagnosis. Daniel Dilling, MD, says.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 11, 2021 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Can AI help screen for early interstitial lung disease on x-rays?
An artificial intelligence (AI) algorithm was able to improve detection of reticula...Read more on AuntMinnie.comRelated Reading: Image search engine boosts chest CT diagnostic accuracy Thoracic radiologists give top tips for CT evaluation of lung parenchyma Machine learning boosts chest CT's performance AI can assess COVID-19 severity on chest x-rays CT textures predict interstitial lung disease survival (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 25, 2021 Category: Radiology Source Type: news

Image search engine boosts chest CT diagnostic accuracy
Using a content-based image retrieval search engine with a deep-learning algorith...Read more on AuntMinnie.comRelated Reading: Specialized CT training helps readers diagnose lung disease Thoracic radiologists give top tips for CT evaluation of lung parenchyma MinIP reconstructions boost CT's COVID-19 performance Machine learning boosts chest CT's performance CT textures predict interstitial lung disease survival (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 15, 2021 Category: Radiology Source Type: news

Statins side effects: Interstitial lung disease among 'serious side effects' - the signs
STATINS are a group of medicines that can lower "bad cholesterol" in the blood. Like all medications, statins can also cause side effects in some cases. One of the more "serious side effects" of atorvastatin includes interstitial lung disease. Here's how to spot it. (Source: Daily Express - Health)
Source: Daily Express - Health - October 15, 2021 Category: Consumer Health News Source Type: news

Gene Variant Tied to Risk for Interstitial Lung Disease in RA
For patients with rheumatoid arthritis, lifetime risks for ILD were 16.8 percent for MUC5B carriers, 6.1 percent for noncarriers (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 28, 2021 Category: Respiratory Medicine Tags: Pathology, Pulmonology, Rheumatology, Journal, Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fibrosis Progression Flies Below the Radar in Subclinical ILD Fibrosis Progression Flies Below the Radar in Subclinical ILD
The findings question the terms"subclinical/preclinical" interstitial lung disease, which may potentially lead to a suboptimal watchful waiting management, according to researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2021 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CT Imaging May Help Distinguish COVID-19 From Interstitial Lung Disease CT Imaging May Help Distinguish COVID-19 From Interstitial Lung Disease
Computed tomography (CT) could be used to help distinguish COVID-19 from systemic sclerosis-related interstitial lung disease (SSc-ILD), researchers suggest.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 13, 2021 Category: Radiology Tags: Infectious Diseases News Source Type: news

New Biomarkers May Predict Course of ILD in Systemic Sclerosis New Biomarkers May Predict Course of ILD in Systemic Sclerosis
Radiographic assessment of interstitial lung disease (ILD) progression and proteins from bronchoalveolar lavage may independently provide better insight into prognoses of patients with systemic sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Gene Variant Confirmed as Strong Predictor of Lung Disease in RA Gene Variant Confirmed as Strong Predictor of Lung Disease in RA
The MUC5B promoter variant is associated with a large increased risk of interstitial lung disease in patients with rheumatoid arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Nintedanib Slows Interstitial Lung Disease in Patients With RA Nintedanib Slows Interstitial Lung Disease in Patients With RA
Nintedanib slowed progression of interstitial lung disease associated with rheumatoid arthritis in a subgroup analysis of a phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news